Three different studies [126,127,128] indicated that anti-PD-1 therapy (camrelizumab) plus TACE regimen is effective and safe, with effective tumor control, improved survival and manageable ICI-related adverse effects, leading to better outcomes than treatment with anti-PD-1 inhibitors alone; moreover, a longer interval between camrelizumab administration and TACE was related to the unsatisfying OS, whereas the timing of administration (before or after TACE) did not significantly influence the results. This evidence concerns the gene PDCD1 and neoplasm.